The elusive promise of myostatin inhibition for muscular dystrophy

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE OF REVIEW: Recent terminations of clinical trials of myostatin inhibitors in muscular dystrophy have raised questions about the predictiveness of mouse models for this therapeutic strategy. RECENT FINDINGS: A variety of myostatin inhibitors have been developed for preclinical and clinical studies. These inhibitors have ameliorated the phenotype of many but not all mouse models of muscular dystrophy. However, randomized double-blinded placebo controlled trials in both pediatric and adult muscular dystrophies have, as of yet, not demonstrated functional improvement. SUMMARY: The present article will review the preclinical promise of myostatin inhibitors, the clinical trial experience to date of these inhibitors in muscular dystrophy, and the potential reasons for the lack of observed translation.

Original languageEnglish (US)
Pages (from-to)621-628
Number of pages8
JournalCurrent opinion in neurology
Volume33
Issue number5
DOIs
StatePublished - Oct 1 2020

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'The elusive promise of myostatin inhibition for muscular dystrophy'. Together they form a unique fingerprint.

Cite this